Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 614

Sort by

Sort Order Select

Journal Articles

Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity

Blood (2021) 138 (14): 1225–1236.

https://doi.org/10.1182/blood.2020009655

Published: 2021

Includes: Supplemental data

Journal Articles

PD-1 loss and T-cell exhaustion in CTCL tumoral T cells

Margarita Sánchez-Beato

Blood (2021) 138 (14): 1201–1203.

https://doi.org/10.1182/blood.2021012676

Published: 2021

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL

Cosmin A Tegla, MD, Alberto M Herrera, MS, Angelina M Seffens, BS, Melania H Fanok, PhD, George Dean, MD, John Kawaoka, MD, Mary E Laird, MD, Yi Fulmer, PhD, Andreas Willerslev-Olsen, PhD, Kenneth B. Hymes, MD, Jo-Ann Latkowski, MD, Niels Odum, MD DMSci, Stefan Feske, MD, Bo Shopsin, MD PhD, Victor Torres, PhD, Marshall E. Kadin, MD, Larisa J Geskin, MD, Sergei B. Koralov, PhD

Blood (2019) 134 (Supplement_1): 659.

https://doi.org/10.1182/blood-2019-131917

Published: 2019

Journal Articles

Total Skin Electron Beam Therapy in Patients with Advanced Cutaneous T Cell Lymphoma Undergoing Allogeneic Stem Cell Transplantation: A Single Centre Experience

Viviana Beatrice Valli, MD, Filippo Grillo Ruggieri, MD, Giorgia Saporiti, MD, Silvia Alberti Violetti, MD, Concetta Schiavone, MD, Federica Irene Grifoni, MD, Maria Cecilia Goldaniga, MD, Francesca Casarin, Valeria Ferla, MD, Luca Baldini, MD PhD, Emilio Berti, MD, Francesco Onida, MD

Blood (2019) 134 (Supplement_1): 2042.

https://doi.org/10.1182/blood-2019-131144

Published: 2019

Journal Articles

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Michelle Janania Martinez, MD, Juan F Garza, MD, Tyler W Snedden, MD, Prathibha Surapaneni, MD, Snegha Ananth, MBBS, Jeremy Rawlings, MD, David J Gregorio, DO, Sushanth Kakarla, MD, Qianqian Liu, PhD, Joel E Michalek, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 2204.

https://doi.org/10.1182/blood-2019-129442

Published: 2019

Journal Articles

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Helen Ma, MD, Enrica Marchi, MD, PhD, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 3486.

https://doi.org/10.1182/blood-2019-123587

Published: 2019

Journal Articles

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Christiane Querfeld, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Paul Frohna, MD PhD PharmD, Nazli Azimi, PhD PharmD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 1557.

https://doi.org/10.1182/blood-2019-129201

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

3D Telomeric Fingerprint of Advanced Cutaneous T-Cell Lymphoma

Marc Nicolas Bienz, MD MSc, Cheryl Taylor-Kashton, Naciba Benlimame, PhD, Tina Petrogiannis-Haliotis, MD PhD, Kevin Pehr, MD, Sabine Mai, PhD, Hans Knecht, MD

Blood (2019) 134 (Supplement_1): 1501.

https://doi.org/10.1182/blood-2019-124559

Published: 2019

Journal Articles

Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging

Christian M. Schuerch, MD PhD, Darci J. Phillips, MD PhD, Salil S. Bhate, MMath, Graham L. Barlow, BA, Steven P Fling, PhD, Nirasha Ramchurren, Robert Pierce, MD, Martin A Cheever, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Garry P. Nolan, PhD

Blood (2019) 134 (Supplement_1): 1521.

https://doi.org/10.1182/blood-2019-125315

Published: 2019

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Neetha Parameswaran, PhD, Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Lisa Durkin, Yvonne Parker, Daniel Lindner, MD PhD, Eric D. Hsi, MD, Deepa Jagadeesh, MDMPH

Blood (2019) 134 (Supplement_1): 1515.

https://doi.org/10.1182/blood-2019-131800

Published: 2019

Journal Articles

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

Joshua C Pritchett, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Jose C Villasboas, MD, Andrew L. Feldman, MD, James R. Cerhan, MD PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 1517.

https://doi.org/10.1182/blood-2019-131145

Published: 2019

Journal Articles

Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models

CHI-HENG WU, PhD, Chen-Yen Yang, PhD, Linlin Wang, MD PhD, Hua-Xin Gao, PhD, Rakhshandehroo Taha, Shervin Afghani, Laura Pincus, MD, Ronald Balassanian, MD, James Rubenstein, Ryan Gill, MD PhD, Sourav Bandyopadhyay, PhD, Frank McCormick, PhD, Mark Moasser, MD, Weiyun Z. Ai, MD PhD

Blood (2019) 134 (Supplement_1): 1578.

https://doi.org/10.1182/blood-2019-122589

Published: 2019

Journal Articles

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Swami P. Iyer, MD, Sattva S Neelapu, MD, Ethan Burns, MD, Ranjit Nair, MBBS,MD, Chitra Hosing, MD, Yago Nieto, MD PhD, Jason R. Westin, MD, Simrit Parmar, MBBS, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Madeleine Duvic, MD, Roberto N. Miranda, MD, Hun Ju Lee, Felipe Samaniego, MD, Sairah Ahmed, MD, Feng Lei, MS, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 1546.

https://doi.org/10.1182/blood-2019-132278

Published: 2019

Journal Articles

A Novel Recurrent Gain-of-Function Mutation of Rltpr Q575E in Adult T Cell Leukemia/Lymphoma

Yuichiro Uchida, Makoto Yoshimitsu, MD PhD, Yuhei Kamada, MD PhD, Naosuke Arima, MD, Kenji Ishitsuka, MD PhD

Blood (2019) 134 (Supplement_1): 1489.

https://doi.org/10.1182/blood-2019-124641

Published: 2019

Journal Articles

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Akihiro Kitadate, MD PhD, Kentaro Narita, MD, Kota Fukumoto, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Youichi Machida, MD, Naoto Takahashi, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 2839.

https://doi.org/10.1182/blood-2019-122799

Published: 2019

Journal Articles

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2019) 134 (Supplement_1): 2844.

https://doi.org/10.1182/blood-2019-129664

Published: 2019

Journal Articles

Single-Antibody Detection of T-Cell Receptor Beta Chain Monotypia Resolves Uncertainties in the Identification and Quantitation of Sézary Cells By Routine Flow Cytometry: Towards Accurate and Unequivocal Blood Staging of Cutaneous T-Cell Lymphomas

Pedro Horna, MD, Min Shi, MD PhD, Dragan Jevremovic, MD PhD, Horatiu Olteanu, MD PhD

Blood (2019) 134 (Supplement_1): 2848.

https://doi.org/10.1182/blood-2019-129477

Published: 2019

NARROW

Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity

PD-1 loss and T-cell exhaustion in CTCL tumoral T cells

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL

Total Skin Electron Beam Therapy in Patients with Advanced Cutaneous T Cell Lymphoma Undergoing Allogeneic Stem Cell Transplantation: A Single Centre Experience

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

3D Telomeric Fingerprint of Advanced Cutaneous T-Cell Lymphoma

Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

A Novel Recurrent Gain-of-Function Mutation of Rltpr Q575E in Adult T Cell Leukemia/Lymphoma

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Single-Antibody Detection of T-Cell Receptor Beta Chain Monotypia Resolves Uncertainties in the Identification and Quantitation of Sézary Cells By Routine Flow Cytometry: Towards Accurate and Unequivocal Blood Staging of Cutaneous T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only